China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

    NEXT STORY
    Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
    PREV STORY
    Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study

    author_avatar
    NASDAQ Market News

    SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH

    author_avatar
    NASDAQ Market News

    Triphase Accelerator Reports Completion of Initial Regulatory Interactions with FDA and Health Canada for TRPH-222 for the Treatment of Lymphoma

    TORONTO and SAN DIEGO, May 01, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a ...

    author_avatar
    NASDAQ Market News